A pharmacokinetic study led by Otani, Payne, and Loftus reported that a single 2‑ml subcutaneous injection of mirikizumab is bioequivalent to two separate 1‑ml injections in healthy volunteers. The trial measured exposure, safety, and tolerability and met bioequivalence criteria. The finding simplifies dosing logistics for biologic administration and could lower administration burden for patients and clinics. Sponsors may use the data to support labeling or device changes that permit single‑injection delivery for approved indications.